About

Bringing innovative world‑class products to you

Mission

To transform patient care through safe, effective, and accessible topical therapies that improve quality of life worldwide.

Vision

To become the global leader in topical pharmaceutical technology, providing high‑quality, affordable, and innovative treatments across multiple therapeutic areas.

Values

  • Innovation — safe, novel solutions to critical healthcare challenges
  • Integrity — treating everyone with honesty and respect
  • Excellence — world‑class products supported by exceptional customer service

History

PresentOngoing product pipeline development, Board and Advisory Board established, strategic partnerships signed.
2024VitaStem now also known as Tetracyte. Company recruits key talent and expands into global markets, harnessing AI to maximise team efficiency, streamline processes and support data driven decision making.
2020VitaStem launched in the U.S. following FDA listing.
2014ViaDerma founded; U.S. patent application initiated.
2013In‑vitro study shows VitaStem (precursor to Tetracyte) eliminates >99% of major bacteria strains.1
2009Dr. Christopher Otiko designs the proprietary topical delivery system.

Global Presence

Remote‑first company headquartered in Las Vegas, with research facilities and offices across North America, Europe, and Asia.

Join the Team

We are not currently recruiting, however talented individuals may email a cover letter and C.V. to info@viaderma.com (subject: "C.V. submission"). We do not work with recruiting agents.

Corporate Responsibility

  • Environmental responsibilityMinimising carbon footprint through remote work and sustainable practices.
  • Ethical sourcingCommitment to fair labour practices and responsible supply chains.
  • Employee well‑beingFostering work‑life balance and continuous personal development.

Partner with ViaDerma

To discuss partnership opportunities, email sales@viaderma.com

Reference

1 Dwivedi, C (2013) A Measure of the Efficacy of VitaStem First Aid Antibiotic Antibiotics Against Six Common Bacteria. Report prepared by South Dakota State University School of Pharmacy in collaboration with Rural Technology Incorporated and a blind third-party laboratory.